Open AccessDose Distributions and Treatment Margins in Ocular Brachytherapy with 106Ru Eye Plaques
Author(s) -
Erik Stöckel,
Marion Eichmann,
Dirk Flühs,
H Sommer,
Eva Biewald,
Norbert Bornfeld,
B. Spaan,
W. Sauerwein
Publication year - 2017
Publication title -
ocular oncology and pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.444
H-Index - 10
eISSN - 2296-4681
pISSN - 2296-4657
DOI - 10.1159/000479558
Subject(s) - brachytherapy , medicine , nuclear medicine , margin (machine learning) , radiation treatment planning , radiation therapy , radiology , machine learning , computer science
Brachytherapy with 106 Ru eye plaques is the most common treatment modality for small to medium-sized uveal melanomas in Europe. So far, no standardized or widely accepted dose prescription protocol for the irradiation of intraocular tumors with 106 Ru eye plaques has been defined. For 125 I plaques, the minimum dose required for tumor control should be at least 85 Gy. Concerning 106 Ru plaques, the dose prescriptions at the University Hospital of Essen foresees minimum doses of 700 Gy to the tumor base and 130 Gy to the tumor apex. These dose prescriptions are expected to ensure sufficient treatment margins. We apply these dose prescriptions to different eye plaque types and tumor sizes and discuss the resulting treatment margins. These investigations are based on Monte Carlo simulations of dose distributions of 3 different eye plaque types. The treatment margin in apical direction has an expansion of at least 0.8 mm for all investigated eye plaques. For symmetrically formed eye plaques, the treatment margin at the base of the tumor goes beyond the visible edge of the plaque. This study focuses on the shape of 85-Gy isodose lines and on treatment margins for different eye plaque types and tumor sizes and shall help exchange knowledge for ocular brachytherapy.